Anlotinib, a multitargeted small‐molecule TKI, effectively combats tumor angiogenesis and inhibits tumor growth by inhibiting vascular endothelial growth factor receptor, platelet‐derived growth factor receptor, fibroblast growth factor receptor, and c‐Kit signaling pathways. This evidence concerns the gene KIT and neoplasm.